tralokinumab · Medicine question

How does tralokinumab block interleukin-13 (IL-13) activity?

iatroX medicinesPublished 8 November 2026

The answer

Answer

Tralokinumab is a fully human IgG4 monoclonal antibody that binds specifically to IL-13 and neutralises its biological activity by preventing interaction with its receptor complex.

Sources for this answer

Adtralza 150 mg solution for injection in pre-filled syringeLeo Laboratories Limited · emc · SmPC §5.1 Pharmacodynamic properties · Version 9Document updated 18 May 2026

Sources checked 8 November 2026

Explore this learning need in CPDTake this topic to CPD, then choose your learning context and available question library.

How early was itch reduction observed with tralokinumab monotherapy in the ECZTRA 1 and ECZTRA 2 atopic dermatitis trials?What effect did tralokinumab have on eczema-related sleep problems at week 16 in the ECZTRA 1, ECZTRA 2 and ECZTRA 3 trials?Can tralokinumab cause a temporary increase in blood eosinophils?How long should an Adtralza tralokinumab pre-filled syringe be allowed to reach room temperature after removal from the refrigerator before injection?How much polysorbate 80 does each Adtralza 150 mg tralokinumab pre-filled syringe contain?

loading page…

Answer

Sources for this answer

More questions about tralokinumab

Answer

Sources for this answer

More questions about tralokinumab

tralokinumab

More clinical questions?